Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.

S Pérez RamírezM Del Monte-MillánS López-TarruellaN Martínez JáñezI Márquez-RodasF Lobo SamperY Izarzugaza PerónC Rubio TerresD Rubio RodríguezJ Á García-SáenzF Moreno AntónP Zamora AuñónM Arroyo YustosM Á Lara ÁlvarezE M Ciruelos GilL Manso SánchezM J Echarri GonzálezJ A Guerra MartínezC Jara SánchezC Bueno MuiñoS García AdriánJ R Carrión GalindoV Valentín MagantoMiguel Martin

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)

Using GEAs to guide adjuvant therapy in ESBC is cost-effective in Spain and has a significant impact on treatment decisions.

Keyphrases

gene expression
early stage
dna methylation
high throughput
squamous cell carcinoma
radiation therapy
replacement therapy
neoadjuvant chemotherapy